Costimulation through NKG2D enhances murine CD8+ CTL function: Similarities and differences between NKG2D and CD28 costimulation

Journal of Immunology

Volumn 175, Issue 5, 2005, Pages 2825-2833

  Markiewicz, Mary A ^a   Carayannopoulos, Leonidas N ^a   Naidenko, Olga V ^a   Matsui, Ken ^a   Burack, W Richard ^a   Wise, Erica L ^a   Fremont, Daved H ^a   Allen, Paul M ^a   Yokoyama, Wayne M ^a   Colonna, Marco ^a   Shaw, Andrey S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; NATURAL KILLER CELL RECEPTOR NKG2D; PEPTIDE; PROTEIN; RAE1 EPSILON PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 23844500629     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.5.2825     Document Type: Article

References (59)

1. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53.
2. Frauwirth, K. A., and C. B. Thompson. 2002. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109: 295-299.
3. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
4. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies. L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
5. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1: 119-126.
6. Girardi, M., D. E. Oppenheim, C. R. Steele, J. M. Lewis, E. Glusac, R. Filler, P. Hobby, B. Sutton, R. E. Tigelaar, and A. C. Hayday. 2001. Regulation of cutaneous malignancy by γδ T cells. Science 294: 605-609.
7. Groh, V., A. Bruhl, H. El-Gabalawy, J. L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100: 9452-9457.
8. + T cells. Blood 103: 3065-3072.
9. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H. Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12: 721-727.
10. Carayannopoulos, L. N., O. V. Naidenko, D. H. Fremont, and W. M. Yokoyama. 2002. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169: 4079-4083.
11. U. Cosman, D., J. Mullberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N. J. Chalupny. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
12. Sutherland, C. L., N. J. Chalupny, K. Schooley, T. VandenBos, M. Kubin, and D. Cosman. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168: 671-679.
13. Chalupny, J. N., C. L. Sutherland, W. A. Lawrence, A. Rein-Weston, and D. Cosman. 2003. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305: 129-135.
14. Conejo-Garcia, I. R., F. Benencia, M. C. Courreges, E. Khang, L. Zhang, A. Mohamed-Hadley, J. M. Vinocur, R. J. Buckanovich, C. B. Thompson, B. Levine, and G. Coukos. 2003. Letal, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol. Ther. 2: 446-451.
15. Bacon, L., R. A. Eagle, M. Meyer, N. Easom, N. T. Young, and J. Trowsdale. 2004. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J. Immunol. 173: 1078-1084.
16. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. RAE1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413: 165-171.
17. Jamieson, A. M., A. Diefenbach, C. W. McMahon, N. Xiong, J. R. Carlyle, and D. H. Raulet. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
18. + T cells. J. Immunol. 174: 1922-1931.
19. Maccalli, C., D. Pende, C. Castelli, M. C. Mingari, P. F. Robbins, and G. Parmiani. 2003. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent antitumor activity. Eur. J. Immunol. 33: 2033-2043.
20. + T cell adoptive immunotherapy. Immunity 13: 265-276.
21. Gilfillan, S., E. L. Ho, M. Cella, W. M. Yokoyama, and M. Colonna. 2002. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3: 1150-1155.
22. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Kuribayashi, L. J. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379.
23. Carayannopoulos, L. N., O. V. Naidenko, J. Kinder, E. L. Ho, D. H. Fremont, and W. M. Yokoyama. 2002. Ligands for murine NKG2D display heterogeneous binding behavior. Eur. J. Immunol. 32: 597-605.
24. Onishi, M., S. Kinoshita, Y. Morikawa, A. Shibuya, J. Phillips, L. L. Lanier, D. M. Gorman, G. P. Nolan, A. Miyajima, and T. Kitamura. 1996. Applications of retrovirus-mediated expression cloning. Exp. Hematol. 24: 324-329.
25. Morita, S., T. Kojima, and T. Kitamura. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 1: 1063-1066.
26. + TCR-transgenic T cells. J. Immunol. 161: 5268-5275.
27. Llera, A. S., F. Viedma, F. Sanchez-Madrid, and J. Tormo. 2001. Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69. J. Biol. Chem. 276: 7312-7319.
28. Beckett, D., E. Kovaleva, and P. J. Schatz. 1999. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8: 921-929.
29. Ho, E. L., L. N. Carayannopoulos, J. Poursine-Laurent, J. Kinder, B. Plougastel, H. R. Smith, and W. M. Yokoyama. 2002. Costimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169: 3667-3675.
30. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221-227.
31. Pont, S., P. Naquet, S. Marchetto, A. Regnier-Vigouroux, D. Blanc, A. Pierres, and M. Pierres. 1986. Identification of 5 topographic domains of the mouse LFA-1 molecule: subunit assignment and functional involvement in lymphoid cell interactions. J. Immunol. 136: 3750-3759.
32. + T cells in vivo. J. Immunol. 163: 2561-2567.
33. + T cells. J. Immunol. 162: 3256-3262.
34. Valenzuela, J., C. Schmidt, and M. Mescher. 2002. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J. Immunol. 169: 6842-6849.
35. Schmidt, C. S., and M. F. Mescher. 2002. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 168: 5521-5529.
36. Chang, J., J. H. Cho, S. W. Lee, S. Y. Choi, S. J. Ha, and Y. C. Sung. 2004. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J. Immunol. 172: 2818-2826.
37. Van der Merwe, P. A., and S. J. Davis. 2003. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 21: 659-684.
38. + T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29: 548-555.
39. Yang, J., H. Zhu, T. L. Murphy, W. Ouyang, and K. M. Murphy. 2001. IL-18-stimulated GADD45 β required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat. Immunol. 2: 157-164.
40. + T cells to innate immunity: IFN-γ secretion induced by IL-12 and IL-18. Eur. J. Immunol. 32: 2807-2816.
41. + T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198: 1583-1593.
42. Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395: 82-86.
43. Krummel, M. F., and M. M. Davis. 2002. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr. Opin. Immunol. 14: 66-74.
44. Dustin, M. L., M. W. Olszowy, A. D. Holdorf, J. Li, S. Bromley, N. Desai, P. Widder, F. Rosenberger, P. A. van der Merwe, P. M. Allen, and A. S. Shaw. 1998. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 94: 667-677.
45. Huppa, J. B., M. Gleimer, C. Sumen, and M. M. Davis. 2003. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat. Immunol. 4: 749-755.
46. Lee, K. H., A. R. Dinner, C. Tu, G. Campi, S. Raychaudhuri, R. Varma, T. N. Sims, W. R. Burack, H. Wu, I. Wang, et al. 2003. The immunological synapse balances T cell receptor signaling and degradation. Science 302: 1218-1222.
47. + T cells. J. Immunol. 174: 4480-4484.
48. Mosmann, T. R., L. Li, and S. Sad. 1997. Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin. Immunol. 9: 87-92.
49. - antitumor T cells. Cancer Res. 64: 2175-2182.
50. Chang, C., J. Dietrich, A. G. Harpur, J. A. Lindquist, A. Haude, Y. W. Loke, A. King, M. Colonna, J. Trowsdale, and M. J. Wilson. 1999. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J. Immunol. 163: 4651-4654.
51. L. J. Immunol. 166: 5331-5335.
52. Okkenhaug, K., L. Wu, K. M. Garza, J. La Rose, W. Khoo, B. Odermatt, T. W. Mak, P. S. Ohashi, and R. Rottapel. 2001. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat. Immunol. 2: 325-332.
53. L, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171: 166-174.
54. Coyle, A. J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J. A. Gonzalo, et al. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13: 95-105.
55. Riley, J. L., P. J. Blair, J. T. Musser, R. Abe, K. Tezuka, T. Tsuji, and C. H. June. 2001. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166: 4943-4948.
56. O'Callaghan, C. A., A. Cerwenka, B. E. Willcox, L. L. Lanier, and P. J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15: 201-211.
57. Favier, B., E. Espinosa, J. Tabiasco, C. Dos Santos, M. Bonneville, S. Valitutti, and J. J. Fournie. 2003. Uncoupling between immunological synapse formation and functional outcome in human γδ T lymphocytes. J. Immunol. 171: 5027-5033.
58. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
59. Hayakawa, Y., J. M. Kelly, J. A. Westwood, P. K. Darcy, A. Diefenbach, D. Raulet, and M. J. Smyth. 2002. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169: 5377-5381.